Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05893225 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Dec 31, 2026 to Feb 28, 2027
    • Site details revised at 5 of 5 sites
    v4
  2. Primary completion date: Aug 15, 2026 to Dec 31, 2026
    • Site details revised at 3 of 5 sites
    • Publications: details revised at 1 of 1 entry
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 15, 2023 to Nov 23, 2023
    • Site details revised at 5 of 5 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination. Patients will continue their DMT treatment: metformin or placebo will be used as add-on study treatment.
Trial Details
NCT Number NCT05893225
Lead Sponsor University Hospital, Antwerp
Collaborators: University Hospital, Ghent, Hasselt University, AZ Sint-Jan AV, Noorderhart Pelt, National MS Center Melsbroek
Conditions
(from sponsor)		 Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Related terms Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive, Nerve Degeneration, Pathologic Processes, Sclerosis
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov